IL6 and rheumatoid arthritis: Across all heatmaps, increased IL-6 and SII levels are consistently associated with worse clinical outcomes, reinforcing the central role of IL-6 as a biomarker for inflammation, disease severity, and progression in RA patients (Figure 7).